Dogwood Therapeutics, Inc. DWTX · Stock Open Dogwood Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Dogwood Therapeutics, Inc. Analysis (DWTX)
Is Dogwood Therapeutics, Inc. a good investment? Dogwood Therapeutics, Inc. (DWTX) is currently trading at 1.03 USD. Market analysts have a consensus price target of 14.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.56. This relatively low multiple may signal that Dogwood Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Dogwood Therapeutics, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -6.37.
Investor FAQ
Does Dogwood Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Dogwood Therapeutics, Inc.?
Dogwood Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 2.20.
Company Profile
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 9, 2024 | 1:25 |
Community Discussion